Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
作者： Datong Zheng , Yanping Chen , Caijie Gao , Yongyue Wei , Guochun Cao
DOI: 10.4161/15384047.2014.956599
关键词:
摘要: Adverse events in platinum-based chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) are major challenges. In this study, we investigated the role of p53 and MDM2 genes predicting adverse NSCLC treated chemotherapy. Specifically, examined p. Pro72Arg (rs1042522), c.14 + 309T>G (rs2279744) c.− 461C > G (rs937282) polymorphisms using PCR-based restriction fragment length polymorphism (RFLP) 444 patients. We determine that 309T was significantly associated severe hematologic overall toxicities chemotherapy, especially aged 57 younger. This also true adenocarcinoma. Second, gastrointestinal heterozygous c.−461C were higher than G/G genotype. Third, − CT haplotype show much those CG haplotype. Moreover, carrying c.−461 –c.14 CG/CT diplotype exhibited CG/CG. Fourth, found interacts both age addition, no significant associations observed between 3 SNPs response to first-line summary, Pro72Arg, toxicity risks following treatment suggest may be used as a candidate biomarker predict who had treatment.
sci-hub.se 参考文章(37)
Rebecca Siegel, Elizabeth Ward, Otis Brawley, Ahmedin Jemal, Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians. ,vol. 61, pp. 212- 236 ,(2011) , 10.3322/CAAC.20121
Deborah B. Zamble, Stephen J. Lippard, Cisplatin and DNA repair in cancer chemotherapy Trends in Biochemical Sciences. ,vol. 20, pp. 435- 439 ,(1995) , 10.1016/S0968-0004(00)89095-7
Ji-hong Pan, Jin-xiang Han, Jian-mei Wu, Hai-nan Huang, Qing-zhong Yu, Li-jun Sheng, MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration. ,vol. 78, pp. 49- 55 ,(2009) , 10.1159/000158454
Chun-Hong Li, Mei-Yan Liu, Wei Liu, Dan-Dan Li, Li Cai, Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pacific Journal of Cancer Prevention. ,vol. 15, pp. 731- 736 ,(2014) , 10.7314/APJCP.2014.15.2.731
A V Khrunin, A Moisseev, V Gorbunova, S Limborska, Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients Pharmacogenomics Journal. ,vol. 10, pp. 54- 61 ,(2010) , 10.1038/TPJ.2009.45
Nicoleta C. Arva, Tamara R. Gopen, Kathryn E. Talbott, Latoya E. Campbell, Agustin Chicas, David E. White, Gareth L. Bond, Arnold J. Levine, Jill Bargonetti, A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells Journal of Biological Chemistry. ,vol. 280, pp. 26776- 26787 ,(2005) , 10.1074/JBC.M505203200
Bin Xu, Yuan-Yuan Mi, Zhi-Chao Min, Gong Cheng, Na Tong, Jun Tao, Peng-Chao Li, Mei-Lin Wang, Jia-Lin Tang, Zheng-Dong Zhang, Ning-Hong Song, Wei Zhang, Hong-Fei Wu, Ning-Han Feng, Li-Xin Hua, None, p53 codon 72 increased biochemical recurrence risk after radical prostatectomy in a southern Chinese population. Urologia Internationalis. ,vol. 85, pp. 401- 405 ,(2010) , 10.1159/000315991
Nancy Price, Sakkaraiappan Ramalingam, Vinay K. Jain, Impact of Genetic Polymorphisms in DNA Repair Enzymes on Drug Resistance in Lung Cancer Clinical Lung Cancer. ,vol. 6, pp. 79- 82 ,(2004) , 10.1016/S1525-7304(11)70205-4
Ji-Youn Han, Geon Kook Lee, Dae Ho Jang, Sung Young Lee, Jin Soo Lee, Association ofp53codon 72 polymorphism andMDM2SNP309 with clinical outcome of advanced nonsmall cell lung cancer Cancer. ,vol. 113, pp. 799- 807 ,(2008) , 10.1002/CNCR.23668
Zhibin Hu, Jiaping Chen, Lingmin Hu, Juncheng Dai, Guangfu Jin, Lin Xu, Hongbing Shen, Jing Dong, Binhui Ren, MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Molecular Carcinogenesis. ,vol. 50, pp. 433- 438 ,(2011) , 10.1002/MC.20727